Sprimeo HCT

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

aliskiren, għall-idroklorotijażide

Available from:

Novartis Europharm Ltd.

ATC code:

C09XA52

INN (International Name):

aliskiren, hydrochlorothiazide

Therapeutic group:

Aġenti li jaġixxu fuq is-sistema renin-angiotensin

Therapeutic area:

Pressjoni għolja

Therapeutic indications:

Trattament ta 'pressjoni għolja essenzjali fl-adulti. Sprimeo HCT huwa indikat f'pazjenti li l-pressjoni tad-demm ma tkunx ikkontrollata sew b'aliskiren jew hydrochlorothiazide użati waħidhom. Sprimeo HCT huwa indikat bħala terapija ta 'sostituzzjoni f'pazjenti li jkunu kontrollati sew b'aliskiren u hydrochlorothiazide, mogħtija flimkien, bl-istess livell ta' doża tat - taħlita.

Authorization status:

Irtirat

Authorization date:

2011-06-23

Patient Information leaflet

                                143
B. FULJETT TA’ TAGĦRIF
Prodott mediċinali li m’għadux awtorizzat
144
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦAL MIN QED JAGĦMEL UŻU
MINNU
SPRIMEO HCT 150 MG/12.5 MG PILLOLI MIKSIJIN B’RITA
SPRIMEO HCT 150 MG/25 MG PILLOLI MIKSIJIN B’RITA
SPRIMEO HCT 300 MG/12.5 MG PILLOLI MIKSIJIN B’RITA
SPRIMEO HCT 300 MG/25 MG PILLOLI MIKSIJIN B’RITA
Aliskiren/hydrochlorothiazide
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek. M’għandekx tgħaddiha lil
persuni oħra. Tista’ tagħmlilhom
il-ħsara, anki jekk ikollhom l-istess sintomi bħal tiegħek.
-
Jekk xi wieħed mill-effetti sekondarji jiggrava jew jekk tinnota xi
effetti sekondarji li mhumiex
imsemmijin f’dan il-fuljett, jekk jogħġbok, għid lit-tabib jew
lill-ispiżjar tiegħek.
F’DAN IL-FULJETT:
1.
X’inhu Sprimeo HCT u għalxiex jintuża
2.
Qabel ma tieħu Sprimeo HCT
3.
Kif għandek tieħu Sprimeo HCT
4.
Effetti sekondarji li jista’ jkollu
5.
Kif taħżen Sprimeo HCT
6.
Aktar tagħrif
1.
X’INHU SPRIMEO HCT U GĦALXIEX JINTUŻA
Il-pilloli ta’ Sprimeo HCT fihom żewġ sustanzi attivi, li jisimhom
aliskiren u hydrochlorothiazide. It-
tnejn li huma jgħinu sabiex tikkontrolla il-pressjoni għolja
(ipertensjoni).
Aliskiren huwa sustanza li tagħmel parti minn klassi ġdida ta’
mediċini li jissejjħu inibituri ta’ renin.
Dawn inaqqsu l-ammont ta’ angiotensin II li l-ġisem jista’
jipproduċi. B’angiotensin II il-vini tad-
demm jidjiequ u l-pressjoni tad-demm togħla. Bit-tnaqqis ta’
angiotensin II, il-vini tad-demm jistrieħu,
u l-pressjoni tad-demm titbaxxa.
Hydrochlorothiazide jagħmel parti minn grupp ta’ mediċini li
jissejħu dijuretiċi thiazide.
Hydrochlorothiazide iżid l-ammont ta’ awrina li tgħaddi, li ukoll
tbaxxi il-pressjoni tad-demm.
Pressjoni tad-demm għolja iżżid l-ammont ta’ xogħol fuq il-qa
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
Prodott mediċinali li m’għadux awtorizzat
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Sprimeo HCT 150 mg/12.5 mg pilloli miksijin b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull pillola miksija b’rita fiha 150 mg aliskiren (bħala
hemifumarate) u 12.5 mg hydrochlorothiazide.
Sustanzi mhux attivi: Kull pillola fiha 25 mg lactose monohydrate u
24.5 mg wheat starch.
Għal-lista kompleta ta’ sustanzi mhux attivi, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita
Pillola bajda, konvessa miż-żewġ naħat, b’għamla ovali miksija
b’rita stampata b’ “LCI” fuq naħa u
“NVR” fuq l-oħra.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Għall-kura ta’ pressjoni għolja naturali f’adulti.
Sprimeo HCT huwa indikat f’pazjenti li jkollhom pressjoni tad-demm
li ma tkunx qed tiġi
ikkontrollata sew b’aliskiren jew hydrochlorothiazide użati
waħidhom.
Sprimeo HCT huwa indikat bħala terapija ta’ sostituzzjoni
f’pazjenti li jkunu kontrollati sew
b’aliskiren u hydrochlorothiazide, mogħtija flimkien, bl-istess
livell ta’ doża tat-taħlita.
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Id-doża irrikkmandata ta’ Sprimeo HCT hija pillola waħda kuljum.
Sprimeo HCT għandu jittieħed
ma’ ikla ħafifa darba kuljum, l-aħjar fl-istess ħin tal-ġurnata.
Il-meraq tal-grejpfrut m’għandux
jittieħed flimkien ma’ Sprimeo HCT.
L-effett kontra l-pressjoni għolja jidher l-aktar fi żmien ġimgħa
u l-akbar effett ġeneralment jidher fi
żmien 4 ġimgħat.
Pożoloġija f’pazjenti li ma jkunux ikkontrollati sew
b’monoterapija ta’ aliskeren jew
hydrochlorothiazide
Jista’ jkun irrikkmandat li d-doża taż-żewġ komponenti
individwali tiġi miżjuda bil-mod b’mod
individwali qabel ma’ jkunu maqluba għat-taħlita fissa. Meta jkun
xieraq fis-sens kliniku, bidla diretta
mill-monoterapija għat-taħlita fissa tista’ tiġi ikkunsidrata.
Sprimeo HCT 150 mg/12.5 mg jista’ jingħata f’pazjenti li jkollhom
il-
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 28-08-2012
Summary of Product characteristics Summary of Product characteristics Bulgarian 28-08-2012
Public Assessment Report Public Assessment Report Bulgarian 28-08-2012
Patient Information leaflet Patient Information leaflet Spanish 28-08-2012
Public Assessment Report Public Assessment Report Spanish 28-08-2012
Patient Information leaflet Patient Information leaflet Czech 28-08-2012
Public Assessment Report Public Assessment Report Czech 28-08-2012
Patient Information leaflet Patient Information leaflet Danish 28-08-2012
Public Assessment Report Public Assessment Report Danish 28-08-2012
Patient Information leaflet Patient Information leaflet German 28-08-2012
Public Assessment Report Public Assessment Report German 28-08-2012
Patient Information leaflet Patient Information leaflet Estonian 28-08-2012
Public Assessment Report Public Assessment Report Estonian 28-08-2012
Patient Information leaflet Patient Information leaflet Greek 28-08-2012
Public Assessment Report Public Assessment Report Greek 28-08-2012
Patient Information leaflet Patient Information leaflet English 28-08-2012
Public Assessment Report Public Assessment Report English 28-08-2012
Patient Information leaflet Patient Information leaflet French 28-08-2012
Public Assessment Report Public Assessment Report French 28-08-2012
Patient Information leaflet Patient Information leaflet Italian 28-08-2012
Public Assessment Report Public Assessment Report Italian 28-08-2012
Patient Information leaflet Patient Information leaflet Latvian 28-08-2012
Public Assessment Report Public Assessment Report Latvian 28-08-2012
Patient Information leaflet Patient Information leaflet Lithuanian 28-08-2012
Summary of Product characteristics Summary of Product characteristics Lithuanian 28-08-2012
Public Assessment Report Public Assessment Report Lithuanian 28-08-2012
Patient Information leaflet Patient Information leaflet Hungarian 28-08-2012
Summary of Product characteristics Summary of Product characteristics Hungarian 28-08-2012
Public Assessment Report Public Assessment Report Hungarian 28-08-2012
Patient Information leaflet Patient Information leaflet Dutch 28-08-2012
Public Assessment Report Public Assessment Report Dutch 28-08-2012
Patient Information leaflet Patient Information leaflet Polish 28-08-2012
Public Assessment Report Public Assessment Report Polish 28-08-2012
Patient Information leaflet Patient Information leaflet Portuguese 28-08-2012
Summary of Product characteristics Summary of Product characteristics Portuguese 28-08-2012
Public Assessment Report Public Assessment Report Portuguese 28-08-2012
Patient Information leaflet Patient Information leaflet Romanian 28-08-2012
Public Assessment Report Public Assessment Report Romanian 28-08-2012
Patient Information leaflet Patient Information leaflet Slovak 28-08-2012
Public Assessment Report Public Assessment Report Slovak 28-08-2012
Patient Information leaflet Patient Information leaflet Slovenian 28-08-2012
Summary of Product characteristics Summary of Product characteristics Slovenian 28-08-2012
Public Assessment Report Public Assessment Report Slovenian 28-08-2012
Patient Information leaflet Patient Information leaflet Finnish 28-08-2012
Public Assessment Report Public Assessment Report Finnish 28-08-2012
Patient Information leaflet Patient Information leaflet Swedish 28-08-2012
Public Assessment Report Public Assessment Report Swedish 28-08-2012
Patient Information leaflet Patient Information leaflet Norwegian 28-08-2012
Summary of Product characteristics Summary of Product characteristics Norwegian 28-08-2012
Patient Information leaflet Patient Information leaflet Icelandic 28-08-2012
Summary of Product characteristics Summary of Product characteristics Icelandic 28-08-2012

View documents history